Wexford Capital’s NextCure NXTC Stock Holding History

Wexford Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-329	Closed	-$43K	–	297
2020 Q4	$43K	Buy	+329	New	+$42.5K	0.01%	205

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Wexford Capital's NXTC Position: Q1 2021 in Review

Wexford Capital sold out of NextCure (NXTC) in Q1 2021, closing a stake of 329 shares — an estimated $43K sold.

Wexford Capital first reported a position in NXTC in Q4 2020 and held it in 1 quarter. The position peaked at $43K in Q4 2020. 92 funds tracked by Wall St. Rank hold NXTC as of Q1 2021.

Wexford Capital reported no remaining NextCure position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 329 NextCure shares in Q1 2021, an estimated $43K.
Wexford Capital first reported a position in NextCure in Q4 2020 and held it in 1 quarter.
Wexford Capital's NextCure position peaked at $43K in Q4 2020.
92 funds tracked by Wall St. Rank held NextCure as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.